Glycostem CEO Troels Jordansen is going to participate the 4th Annual Cell & Gene Therapy Innovation Leaders Summit 2022, as keynote speaker, in Berlin, Germany.
Glycostem CEO Troels Jordansen and CMO Kai Pinkernell, MD, MBA to participate and give keynote speech at the Allogeneic Cell Therapies Summit Europe 2022 during 19th-20th January, 2022 in London, UK.
19th Jan 2022
09:00-10:00 GMT: Keynote Panel: Achieving an Off-the-Shelf Future for Europe
17:00-17:30 GMT: Off-the-Shelf NK Cells in European AML Clinical Trial
Glycostem to participant the 63rd ASH Annual Meeting & Exposition virtually to present abstract online, about Clinical data of the first two acute myeloid leukemia patients enrolled in the phase I/IIa WiNK clinical trial.
Title: Allogeneic, CD34+, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease
Session Date/Time: 11th December 11, 2021 5:30 PM - 7:30 PM EST
Glycostem Chief Development Officer Volker Huppert to present at Next Generation Cell & Gene Therapy Conference about Scaling NK Manufacturing on 8th Nov.
Glycostem to attend 8th European Drug Discovery Strategic Summit in Amsterdam, Netherlands on 4th & 5th November 2021.
Glycostem Chief Development Officer Volker Huppert to present 29th Oct at Cell UK 2021 organized by Oxford Global Conferences, to give a keynote speech about manufacturing scaling of CAR-NK product. This in-person event will also be streamed online.